儿童癌症幸存者的睾丸功能：基于异环磷酰胺和环磷酰胺方案的比较研究。
Testicular function of survivors of childhood cancer: a comparative study between ifosfamide- and cyclophosphamide-based regimens.
作者信息
Ridola Vita, Fawaz Oumaya, Aubier Françoise, Bergeron Christophe, de Vathaire Florent, Pichon Fabienne, Orbach Daniel, Gentet Jean Claude, Schmitt Claudine, Dufour Christelle, Oberlin Odile
机构信息
Department of Pediatric and Adolescent Oncology, Institut Gustave Roussy, Villejuif, France.
出版信息
Eur J Cancer. 2009 Mar;45(5):814-8. doi: 10.1016/j.ejca.2009.01.002. Epub 2009 Feb 11.
PURPOSE
This study aimed at comparing gonadal toxicity of ifosfamide versus cyclophosphamide received during childhood.
METHODS
The evaluation was based on basal FSH measurement. LH and testosterone were also measured in most of the patients. One hundred patients had received ifosfamide and 59 had received cyclophosphamide.
RESULTS
Median age at treatment was 11.2 years. The median interval since treatment was 10.7 years (range 4.1-20.2) and median age at evaluation was 21.4 years (17.5-36.1). The median dose of ifosfamide and of cyclophosphamide was 54 g/m(2) (18-114) and 8.3 g/m(2) (4.6-22), respectively. All but two males had normal testosterone levels. FSH was abnormal in 28/59 patients (47.5%) after receiving cyclophosphamide and was within the normal range in 94/100 patients (94%) after receiving ifosfamide.
CONCLUSIONS
These results show that ifosfamide is associated with a lower risk of gonadal damage than cyclophosphamide. The risk of abnormal FSH increased with the cumulative dose of cyclophosphamide.
目的
本研究旨在比较儿童期接受异环磷酰胺与环磷酰胺的性腺毒性。
方法
评估基于基础促卵泡生成素（FSH）测量。大多数患者还测量了促黄体生成素（LH）和睾酮。100例患者接受了异环磷酰胺，59例接受了环磷酰胺。
结果
治疗时的中位年龄为11.2岁。自治疗后的中位间隔时间为10.7年（范围4.1 - 20.2年），评估时的中位年龄为21.4岁（17.5 - 36.1岁）。异环磷酰胺和环磷酰胺的中位剂量分别为54 g/m²（18 - 114）和8.3 g/m²（4.6 - 22）。除两名男性外，所有男性的睾酮水平均正常。接受环磷酰胺后，59例患者中有28例（47.5%）促卵泡生成素异常，接受异环磷酰胺后，100例患者中有94例（94%）促卵泡生成素在正常范围内。
结论
这些结果表明，与环磷酰胺相比，异环磷酰胺导致性腺损伤的风险较低。促卵泡生成素异常的风险随环磷酰胺累积剂量的增加而增加。
Zotero 插件